Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol + MTX in RA Patients with Incomplete Response to MTX
NCT00993317Phase 3Completed
- Sponsor
- Otsuka Holdings
- Start
- Oct 2009
- Primary completion
- Aug 2011
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by Otsuka Holdings. Started Oct 2009; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00993317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00993317.